NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
Clinical Trials
7 trialsNCT06926868 2026-04-01
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06910072 2025-04-04
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT03150576 2022-11-14
PARTNER
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Recruiting
NCT03674242 2022-08-01
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
ERYtech Pharma
Phase 2/3 Terminated
NCT04907344 2021-05-28
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed